Guardion Health Sciences, Inc.
GHSI · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | 0.29 | -0.05 |
| FCF Yield | -8.50% | -6.50% | -19.35% | -8.16% |
| EV / EBITDA | 1.56 | -4.31 | -0.65 | -2.27 |
| Quality | ||||
| ROIC | -9.60% | -11.17% | 39.34% | -6.75% |
| Gross Margin | 49.85% | 39.30% | 45.81% | 43.76% |
| Cash Conversion Ratio | 0.55 | 0.16 | -3.10 | -2.06 |
| Growth | ||||
| Revenue 3-Year CAGR | -6.51% | 8.73% | 19.19% | 35.81% |
| Free Cash Flow Growth | -43.14% | 42.73% | -71.88% | -87.59% |
| Safety | ||||
| Net Debt / EBITDA | 10.88 | 4.02 | 9.25 | 9.97 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.47 | 0.85 | 0.59 | 0.77 |
| Cash Conversion Cycle | -71.93 | 148.18 | 186.42 | 122.86 |